Literature DB >> 33665226

Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion.

David S J Allan1, Mala Chakraborty1, Giacomo C Waller1, Michael J Hochman1, Akkapon Poolcharoen1, Robert N Reger1, Richard W Childs1.   

Abstract

Transduction of primary human natural killer (NK) cells with lentiviral vectors has historically been challenging. We sought to evaluate multiple parameters to optimize lentiviral transduction of human peripheral blood NK cells being expanded to large numbers using a good manufacturing practice (GMP)-compliant protocol that utilizes irradiated lymphoblastoid (LCL) feeder cells. Although prestimulation of NK cells with interleukin (IL)-2 for 2 or more days facilitated transduction with vesicular stomatitis virus glycoprotein (VSVG)-pseudotyped lentivirus, there was a subsequent impairment in the capacity of transduced NK cells to proliferate when stimulated with LCL feeder cells. In contrast, incubation of human NK cells with LCL feeder cells plus IL-2 before transduction in the presence of the TBK1 inhibitor BX795 resulted in efficient lentiviral integration (mean of 23% transgene+ NK cells) and successful subsequent proliferation of the transduced cells. Investigation of multiple internal promoter sequences within the same lentiviral vector revealed differences in percentage and level of transgene expression per NK cell. Bicistronic lentiviral vectors encoding both GFP and proteins suitable for the isolation of transduced cells with magnetic beads led to efficient transgene expression in NK cells. The optimized approaches described herein provide a template for protocols that generate large numbers of fully functional and highly purified lentivirus-transduced NK cells for clinical trials.

Entities:  

Year:  2021        PMID: 33665226      PMCID: PMC7890427          DOI: 10.1016/j.omtm.2021.01.008

Source DB:  PubMed          Journal:  Mol Ther Methods Clin Dev        ISSN: 2329-0501            Impact factor:   6.698


  41 in total

1.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1.

Authors:  Janna Seifried; Stephen Soonthornvacharin; Sunnie M Yoh; Monika Schneider; Rana E Akleh; Kevin C Olivieri; Paul D De Jesus; Chunhai Ruan; Elisa de Castro; Pedro A Ruiz; David Germanaud; Vincent des Portes; Adolfo García-Sastre; Renate König; Sumit K Chanda
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

Review 3.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

4.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

5.  Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells.

Authors:  M Rosenzweig; M Connole; R Glickman; S P Yue; B Noren; M DeMaria; R P Johnson
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Authors:  Maria Berg; Andreas Lundqvist; Philip McCoy; Leigh Samsel; Yong Fan; Abdul Tawab; Richard Childs
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

7.  Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.

Authors:  Veronika Kremer; Maarten A Ligtenberg; Rosa Zendehdel; Christina Seitz; Annet Duivenvoorden; Erik Wennerberg; Eugenia Colón; Ann-Helén Scherman-Plogell; Andreas Lundqvist
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

8.  Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.

Authors:  Mattias Carlsten; Ali Namazi; Robert Reger; Emily Levy; Maria Berg; Cynthia St Hilaire; Richard W Childs
Journal:  Oncoimmunology       Date:  2018-11-02       Impact factor: 8.110

9.  Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.

Authors:  Aurelien B L Colamartino; William Lemieux; Panojot Bifsha; Simon Nicoletti; Nitin Chakravarti; Joaquín Sanz; Hugo Roméro; Silvia Selleri; Kathie Béland; Mélanie Guiot; Camille Tremblay-Laganière; Renée Dicaire; Luis Barreiro; Dean A Lee; Els Verhoeyen; Elie Haddad
Journal:  Front Immunol       Date:  2019-12-16       Impact factor: 7.561

10.  Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

Authors:  Mattias Carlsten; Emily Levy; Amrita Karambelkar; Linhong Li; Robert Reger; Maria Berg; Madhusudan V Peshwa; Richard W Childs
Journal:  Front Immunol       Date:  2016-03-22       Impact factor: 7.561

View more
  8 in total

1.  Inhibition of O-GlcNAcylation Decreases the Cytotoxic Function of Natural Killer Cells.

Authors:  Daniel Feinberg; Parameswaran Ramakrishnan; Derek P Wong; Abhishek Asthana; Reshmi Parameswaran
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

Review 2.  Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.

Authors:  Ying Gong; Roel G J Klein Wolterink; Jianxiang Wang; Gerard M J Bos; Wilfred T V Germeraad
Journal:  J Hematol Oncol       Date:  2021-05-01       Impact factor: 17.388

Review 3.  Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.

Authors:  Erica L Heipertz; Evan R Zynda; Tor Espen Stav-Noraas; Andrew D Hungler; Shayne E Boucher; Navjot Kaur; Mohan C Vemuri
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

Review 4.  Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing.

Authors:  Mark Gurney; Soumyadipta Kundu; Shubham Pandey; Michael O'Dwyer
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

5.  High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.

Authors:  Joseph Andrew Clara; Emily R Levy; Robert Reger; Stefan Barisic; Long Chen; Elena Cherkasova; Mala Chakraborty; David S J Allan; Richard Childs
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

6.  Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.

Authors:  Maren Soldierer; Arthur Bister; Corinna Haist; Aniththa Thivakaran; Sevgi Can Cengiz; Stephanie Sendker; Nina Bartels; Antonia Thomitzek; Denise Smorra; Maryam Hejazi; Markus Uhrberg; Kathrin Scheckenbach; Cornelia Monzel; Constanze Wiek; Dirk Reinhardt; Naghmeh Niktoreh; Helmut Hanenberg
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 7.  CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

Authors:  Mohamad Sabbah; Ludovic Jondreville; Claire Lacan; Francoise Norol; Vincent Vieillard; Damien Roos-Weil; Stéphanie Nguyen
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

Review 8.  Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.

Authors:  Dayane Schmidt; Sima Ebrahimabadi; Kauan Ribeiro de Sena Gomes; Graziela de Moura Aguiar; Mariane Cariati Tirapelle; Renata Nacasaki Silvestre; Júlia Teixeira Cottas de Azevedo; Dimas Tadeu Covas; Virginia Picanço-Castro
Journal:  Immunother Adv       Date:  2022-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.